Table 1.
Ex-vivo database model statistics and demographics
| Cut | Coag | Cut and coag combined | ||
|---|---|---|---|---|
| Total | Sampling points | 634 | 524 | 1158 |
| Samples | 190 | 169 | 359 | |
| Patients | 108 | 105 | 113 | |
| Normal (B1 and B2) | Sampling points | 510 | 422 | 932 |
| Samples | 133 | 120 | 253 | |
| Patients | 95 | 93 | 103 | |
| Tumour (B5a and B5b) | Sampling points | 124 | 102 | 226 |
| Samples | 57 | 49 | 106 | |
| Patients | 53 | 46 | 56 | |
| Tumour type | IDC | 39 | 33 | 42 |
| ILC | 8 | 7 | 8 | |
| IMC | 4 | 4 | 4 | |
| DCIS | 2 | 2 | 2 | |
| Tumour receptor status | ER+/HER2–negative | 42 | 37 | 45 |
| ER+/HER2–positive | 3 | 3 | 3 | |
| ER–/HER2–positive | 3 | 2 | 3 | |
| Triple-negative | 3 | 2 | 3 | |
| DCIS | 2 | 2 | 2 | |
| Age (mean) | All | 57.56 | 57.16 | 57.15 |
| Normal | 57.14 | 56.63 | 56.51 | |
| Tumour | 60.94 | 62.13 | 60.73 | |
| Model statistics | Sensitivity | 94.7% | 93.9% | 93.4% |
| Specificity | 96.2% | 95.0% | 94.9% | |
| Accuracy | 95.8% | 94.7% | 94.4% | |
Statistics and demographics displayed for three ex-vivo models (Cut, Coag and Combined). IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, IMC invasive mucinous carcinoma, DCIS ductal carcinoma in situ, ER+ oestrogen receptor positive, ER– oestrogen receptor negative, HER2+ human epidermal growth factor receptor 2 positive, HER– human epidermal growth factor receptor 2 negative